Dr. Reddy’s Laboratories shuts units after a cyber attack
The drugmaker isolates all data center services, shuts down some production facilities temporarily
India’s leading pharmaceutical company Dr. Reddy’s Laboratories has temporarily shut down some of its production facilities in the wake of a cyber attack in the early hours of Thursday.
While a statement from the drugmaker said it had isolated all data center services to take required preventive actions after the detection of a cyber attack, sources said as a precautionary measure the company had also temporarily shut down some of the production facilities. Details of the units were not immediately available.
In an intimation to the stock exchange, the company said “in the wake of a detected cyber-attack, we have isolated all data center services to take required preventive actions.”
CIO Mukesh Rathi said, “we are anticipating all services to be up within 24 hours and we do not foresee any major impact on our operations due to this incident.”
Besides involving one of the biggest names in the Indian corporate sector, the cyber attack comes close on the heels of Dr. Reddy’s receiving Drugs Controller General of India (DCGI) approval to conduct Phase 2/3 human clinical trial for Sputnik V vaccine, developed by Russia, in the country.
This followed Russia’s sovereign wealth fund RDIF, which is piloting the COVID-19 vaccine candidate, announcing last month’s collaboration with Dr. Reddy’s for clinical trials and distribution of the vaccine in India.
On Saturday, the drugmaker and Russian Direct Investment Fund (RDIF) had announced receipt of the DCGI approval for an adaptive phase 2/3 human clinical trial for the Sputnik V vaccine. It was a multi-center and randomized controlled study, which would include safety and immunogenicity study, they had said in a joint statement.
As per the plan, the RDIF intends to supply 100 million doses of the vaccine to Dr. Reddy’s. Subject to completion of successful trials and registration of the vaccine by regulatory authorities in India, deliveries could potentially begin in late 2020, the RDIF had said in September. Sputnik V vaccine has been developed by Russia’s Gamaleya National Research Institute of Epidemiology and Microbiology and is the world’s first registered vaccine against COVID-19 based on the human adenoviral vectors platform.
A letter from the Editor
Your support for our journalism is invaluable. It’s a support for truth and fairness in journalism. It has helped us keep apace with events and happenings.
The Hindu has always stood for journalism that is in the public interest. At this difficult time, it becomes even more important that we have access to information that has a bearing on our health and well-being, our lives, and livelihoods. As a subscriber, you are not only a beneficiary of our work but also its enabler.
We also reiterate here the promise that our team of reporters, copy editors, fact-checkers, designers, and photographers will deliver quality journalism that stays away from vested interest and political propaganda.